Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
Osmotica Pharmaceuticals, which develops and sells extended-release neurology drugs, raised $47 million by offering 6.65 million shares at $7, in line with the revised price guidance. The company had previously filed to offer 8.3 million shares at a range of $14...read more
Osmotica Pharmaceuticals, which develops and sells extended-release neurology drugs, lowered the proposed deal size for its upcoming IPO on Wednesday.
The Bridgewater, NJ-based company now plans to raise $58 million by offering 8.3 million shares at a price...read more
The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more
US IPO Weekly Recap: IPOs are put through the ringer with 7 completed deals
Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
Extended release drug maker Osmotica Pharmaceuticals prices half-sized IPO at $7
Osmotica Pharmaceuticals, which develops and sells extended-release neurology drugs, raised $47 million by offering 6.65 million shares at $7, in line with the revised price guidance. The company had previously filed to offer 8.3 million shares at a range of $14...read more
Extended release drug maker Osmotica Pharmaceuticals decreases proposed IPO deal size
Osmotica Pharmaceuticals, which develops and sells extended-release neurology drugs, lowered the proposed deal size for its upcoming IPO on Wednesday. The Bridgewater, NJ-based company now plans to raise $58 million by offering 8.3 million shares at a price...read more
US IPO Weekly Recap: Despite sell-off, 4 IPOs price with unicorn Anaplan up 43%
The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more